Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies

By sjmartinez • March 13, 2025

Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, Wander SA, Bardia A, Ko N, Moy B, Ellisen LW, Isakoff SJ. Dynamic HER2-low status among patients with triple negative breast cancer (TNBC) and the impact of repeat biopsies. NPJ Breast Cancer. 2025 Mar 11;11(1):27. doi: 10.1038/s41523-025-00741-y. PMID: 40069204.

Tags: Hematology/Oncology, Publications

Emerin Dysregulation Drives the Very-Small-Nuclear Phenotype and Lineage Plasticity that Associates with a Clinically Aggressive Subtype of Prostate Cancer

Zhang L, Teng PC, Cavassani KA, Wang J, Grasso C, Watson J, Chen Z, Tu KH, Salumbides B, Rohena-Rivera K, Gevorkian L, Kim M, You[...]

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]